Chiron Corporation

Tethys Bioscience, Inc.

Bayer Corporation

Other

Health Diagnostic Laboratory, Inc.

Chiron Diagnostics Corporation

Qui-lim Choo

George Kuo

Michael Houghton

Michael S. Urdea

Thomas Horn

Jang Han

Amy J. Weiner

Brian D. Warner

Michael S Urdea

Janice A Kolberg

Brian David Warner

Bruce D Irvine

Michael P McKenna

Chu-an Chang

Mark L Collins

Patrick J Sheridan

Joyce A Running

Timothy J Fultz

Patrick A Arensdorf

Tai-An Cha

Eileen Beall

Jennifer M Clyne

Ray Sanchez-Pescador

Qui-Lim Choo

Jang Hyun Han

Amy J Weiner

P Scott Eastman

Rick T Smethers

Lev J Leytes

Robert R Shadel

Lu-Ping Shen

Diana J Besemer

Scott Eastman

Brian D Warner

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.

Diabetes-related biomarkers and methods of use thereof

Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 &#x3bc;L or less of a legacy clinical sample.

Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets

The invention provides methods, compositions, and kits for multiplex fractionation of proteins in a sample. Protein-binding molecules, such as small epitope antibodies or small epitope aptamers, are used for multiplex fractionation of proteins in a protein containing sample. Detection of fractionated proteins may be used for characterization of proteins in a sample in applications such as expression profiling, identification and/or quantification of proteins in a sample, and identification or detection of biomarkers.

Multiplex protein fractionation

Purification of oligomers using dual-end selection

Novel DNA probe sequences for detection of HIV in a sample in a solution phase sandwich hybridization assay are described. Amplified nucleic acid hybridization assays using the probes are exemplified.

HIV probes for use in solution phase sandwich hybridization assays

The present application features nucleic acid, peptide and antibody compositions relating to genotypes of hepatitis C virus and methods of using such compositions for diagnostic and therapeutic purposes.

HCV genomic sequences for diagnostics and therapeutics

Synthetic oligonucleotides which are useful as probes in a solution phase sandwich hybridization assay for the detection of HTLV-1 are described. The oligonucleotides have a first segment comprising a nucleotide sequence substantially complementary to a segment of HTLV-1 nucleic acid, and a second segment comprising a nucleotide sequence which is not complementary to HTLV-1 nucleic acid but is substantially complementary to an oligonucleotide unit of a nucleic acid multimer or to an oligonucleotide bound to a solid phase. Amplified nucleic acid hybridization assays using the probes are exemplified.

HTLV-1 probes for use in solution phase sandwich hybridization assays

Methods are provided for substantially reducing background signals encountered in nucleic acid hybridization assays. The method is premised on the elimination or significant reduction of the phenomenon of nonspecific hybridization, so as to provide a detectable signal which is produced only in the presence the target polynucleotide of interest. In addition, a novel method for the chemical synthesis of isoguanosine or 2&prime;-deoxy-isoguanosine is provided. The invention also has applications in antisense and aptamer therapeutics and drug discovery.

Reduction of nonspecific hybridization by using novel base-pairing schemes

This invention relates to a method of measuring the relative populations of first and second variants of a target nucleotide sequence of a target genome in a sample utilizing an amplification step, followed by probing with first and second variant probes and a control probe. Specific embodiments include an assay to monitor the conversion of codon 215 for HIV-1 reverse transcriptase from wild type to mutant form.

Differential hybridization for relative quantification of variant populations

Growing community of inventors

Alamo, CA, United States of America

Michael S Urdea